Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 70Thoracic 3Sarcoma 2Gynecologic 2Other solid neoplasm 1

Conditions

NSCLC 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 551Pemetrexed 404Cisplatin 401Paclitaxel 273Docetaxel 255Gemcitabine 218pembrolizumab 191Bevacizumab 190Erlotinib Hydrochloride 184Radiotherapy 181Etoposide 147durvalumab 140Nivolumab 134Drug Therapy 127osimertinib 107atezolizumab 92Gefitinib 74Radiosurgery 72anlotinib 69Vinorelbine 68tislelizumab 52Irinotecan 51Ipilimumab 50130-nm albumin-bound paclitaxel 50Taxes 48Surgical Procedures, Operative 46Cetuximab 46sintilimab 45Albumin-Bound Paclitaxel 45apatinib 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × HMPL-013 × Thoracic × Clear all
NCT02590965 2020-02-13

A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03684967 2019-11-19

Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC

Hutchmed

Phase 2 Withdrawn
Thoracic

Lung Neoplasms

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
50 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡